American Heart Journal
Volume 148, Issue 5 , Pages 743-746 , November 2004

Expanding indications for natriuretic peptides: Importance of Better New (research) Protocols

  • Ramachandran S. Vasan, MD

      Affiliations

    • Corresponding Author InformationReprint requests: Ramachandran S. Vasan, MD, Boston University School of Medicine & The Framingham Heart Study, 73 Mt. Wayte Avenue, Suite 2, Framingham, MA 01702-5827, USA

References 

  1. Mark DB, Felker GM. B-Type natriuretic peptide—a biomarker for all seasons?. N Engl J Med. 2004;350:718–720
  2. Cowie MR, Jourdain P, Maisel A, et al.  Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J. 2003;24:1710–1718
  3. Knudsen CW, Omland T, Clopton P, et al.  Diagnostic value of B-Type natriuretic peptide and chest radiographic findings in patients with acute dyspnea. Am J Med. 2004;116:363–368
  4. McCullough PA, Nowak RM, McCord J, et al.  B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure (analysis from Breathing Not Properly (BNP) multinational study). Circulation. 2002;106:416–422
  5. Mueller C, Scholer A, Laule-Kilian K, et al.  Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med. 2004;350:647–654
  6. McDonagh TA, Robb SD, Murdoch DR, et al.  Biochemical detection of left-ventricular systolic dysfunction. Lancet. 1998;351:9–13 see comments
  7. Talwar S, Squire IB, Davies JE, et al.  Plasma N-terminal pro-brain natriuretic peptide and the ECG in the assessment of left-ventricular systolic dysfunction in a high risk population. Eur Heart J. 1999;20:1736–1744
  8. Maisel A. B-type natriuretic peptide levels (a potential novel “white count” for congestive heart failure). J Card Fail. 2001;7:183–193
  9. de Lemos JA, Morrow DA, Bentley JH, et al.  The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001;345:1014–1021
  10. Packer M. Should B-type natriuretic peptide be measured routinely to guide the diagnosis and management of chronic heart failure?. Circulation. 2003;108:2950–2953
  11. Kazanegra R, Cheng V, Garcia A, et al.  A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure (a pilot study). J Card Fail. 2001;7:21–29
  12. Kruger S, Graf Ju, Kunz D, et al.  Brain natriuretic peptide levels predict functional capacity in patients with chronic heart failure. J Am Coll Cardiol. 2002;40:718–722
  13. Troughton RW, Prior DL, Pereira JJ, et al.  Plasma B-type natriuretic peptide levels in systolic heart failure (importance of left ventricular diastolic function and right ventricular systolic function). J Am Coll Cardiol. 2004;43:416–422
  14. Jaeschke R, Guyatt GH, Sackett DL. Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. JAMA. 1994;271:703–707
  15. Heidenreich PA, Gubens MA, Fonarow GC, et al.  Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol. 2004;43:1019–1026
  16. Suzuki T, Yamaoki K, Nakajima O, et al.  Screening for cardiac dysfunction in asymptomatic patients by measuring B-type natriuretic peptide levels. Jpn Heart J. 2000;41:205–214
  17. Nagueh SF, Mikati I, Kopelen HA, et al.  Doppler estimation of left ventricular filling pressure in sinus tachycardia (a new application of tissue Doppler imaging). Circulation. 1998;98:1644–1650
  18. Ommen SR, Nishimura RA, Appleton CP, et al.  Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures (a comparative simultaneous Doppler-catheterization study). Circulation. 2000;102:1788–1794
  19. Newman TB, Browner WS, Cummings SR. Designing studies of medical tests. In:  Hulley SB,  Cummings SR,  Browner WS, et al. editor. Designing clinical research. Philadelphia: Lippincott Williams & Wilkins; 2001;p. 175–194
  20. Mansencal N, Bouvier E, Joseph T, et al.  Value of tissue Doppler imaging to predict left ventricular filling pressure in patients with coronary artery disease. Echocardiography. 2004;21:133–138
  21. Rivas-Gotz C, Manolios M, Thohan V, et al.  Impact of left ventricular ejection fraction on estimation of left ventricular filling pressures using tissue Doppler and flow propagation velocity. Am J Cardiol. 2003;91:780–784
  22. Firstenberg MS, Levine BD, Garcia MJ, et al.  Relationship of echocardiographic indices to pulmonary capillary wedge pressures in healthy volunteers. J Am Coll Cardiol. 2000;36:1664–1669
  23. Loke I, Squire IB, Davies JE, et al.  Reference ranges for natriuretic peptides for diagnostic use are dependent on age, gender and heart rate. Eur J Heart Fail. 2003;5:599–606
  24. Redfield MM, Rodeheffer RJ, Jacobsen SJ, et al.  Plasma brain natriuretic peptide concentration (impact of age and gender). J Am Coll Cardiol. 2002;40:976–982
  25. Wang TJ, Larson MG, Levy D, et al.  Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol. 2002;90:254–258
  26. Cowie MR, Struthers AD, Wood DA, et al.  Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 1997;350:1349–1353 see comments
  27. Kucher N, Printzen G, Goldhaber SZ. Prognostic role of brain natriuretic peptide in acute pulmonary embolism. circulation. 2003;107:2545–2547
  28. Bibbins-Domingo K, Ansari M, Schiller NB, et al.  B-type natriuretic peptide and ischemia in patients with stable coronary disease (data from the Heart and Soul Study). Circulation. 2003;108:2987–2992
  29. Luchner A, Burnett JC, Jougasaki M, et al.  Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens. 2000;18:1121–1128
  30. Maron BJ, Tholakanahalli VN, Zenovich AG, et al.  Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy. Circulation. 2004;109:984–989
  31. Nagueh SF, McFalls J, Meyer D, et al.  Tissue Doppler imaging predicts the development of hypertrophic cardiomyopathy in subjects with subclinical disease. Circulation. 2003;108:395–398
  32. Luchner A, Burnett JC, Jougasaki M, et al.  Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism (evidence from a population-based study). J Am Coll Cardiol. 1998;32:1839–1844
  33. McDonagh TA, Holmer S, Raymond I, et al.  NT-proBNP and the diagnosis of heart failure (a pooled analysis of three European epidemiological studies). Eur J Heart Fail. 2004;6:269–273
  34. Tang WHW, Girod JP, Lee MJ, et al.  Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure. Circulation. 2003;108:2964–2966
  35. Kitzman DW, Little WC, Brubaker PH, et al.  Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA. 2002;288:2144–2150
  36. Mottram PM, Leano R, Marwick TH. Usefulness of B-type natriuretic peptide in hypertensive patients with exertional dyspnea and normal left ventricular ejection fraction and correlation with new echocardiographic indexes of systolic and diastolic function. Am J Cardiol. 2003;92:1434–1438
  37. Maisel AS, McCullough PA. Cardiac natriuretic peptides (a proteomic window to cardiac function and clinical management). Rev Cardiovasc Med. 2003;4(Suppl 4):S3–12

PII: S0002-8703(04)00323-0

doi: 10.1016/j.ahj.2004.04.044

American Heart Journal
Volume 148, Issue 5 , Pages 743-746 , November 2004

Article Tools